Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

NCT01166126 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

NIH

Sponsor class

Conditions

Mucosal Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions

DRUG: temsirolimus
DRUG: selumetinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)